Why Partner?
Position Your Company at the Forefront of This Rapidly Evolving Industry
The Novel Targeting Moiety & Payload Conjugates Summit Europe uniquely positions itself as the premier platform for uniting 60+ leaders in novel drug conjugate design and development. Unlike other events, this summit offers unparalleled opportunities for service providers to connect with top experts addressing shared challenges in optimizing antibody fragments, peptides, oligonucleotides, linkers, and conjugation technologies.
With a focus on streamlining research and advancing innovative payloads from discovery to preclinical, to clinical stages, this event is your chance to showcase solutions, collaborate on groundbreaking projects, and shape the future of bioconjugate drug development in Europe. Don’t miss the opportunity to partner with us and drive innovation in this dynamic field.Â
Experts are Seeking Solutions In:
Optimised Antibody Fragment and Peptide Selection
Custom antibody fragment and peptide synthesis with high affinity and specificity for target molecules are in demand. Â
Advanced Linker Technologies
Innovative linker chemistries that ensure stable conjugation and controlled payload release, including cleavable and non-cleavable linkers tailored for different therapeutic payloads.
Cutting-Edge Conjugation Techniques
State-of-the-art conjugation methods that provide a high drug-to-molecule ratio and homogeneity. Â
Analytical and Characterization Services
Detailed analytical services to characterize bioconjugates, including mass spectrometry, HPLC, and bioassays. Â
Scalable Manufacturing SolutionsÂ
Robust GMP compliant manufacturing processesfor high-quality bioconjugates that can be scaled from preclinical to commercial stages. Â
Engage with European Biotech Innovators
Tailored Partnership Opportunities
Exclusive Networking Opportunities
Showcase Your Expertise
Drive Industry Innovation
To Find Out more:
